Maze Therapeutics, Inc.

Maze Therapeutics, Inc.

MAZE·NASDAQ

$25.06

+3.2%
HealthcareBiotechnology

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$1.39B
EPS-3.0500
P/E Ratio-8.22
Earnings Date08/11/2026

No Dividend Yield Data

MAZE has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

MAZE has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

MAZE has not reported any net dividends paid values in the available annual periods.

Maze Therapeutics, Inc.

Maze Therapeutics, Inc. Dividend History

MAZE · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

MAZE Dividend Payment History

MAZE · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
maze

Maze Therapeutics, Inc. Payout Ratio Analysis

MAZE · NASDAQ
Dividends Paid
0.00
2025
Net Income
-131.12M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.